These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33738725)

  • 41. Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a.
    Wei Y; Fan Y; Huang S; Lv J; Zhang Y; Hao Z
    Phytomedicine; 2024 Jan; 122():155163. PubMed ID: 37924689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of loperamide in gastrointestinal disorders.
    Hanauer SB
    Rev Gastroenterol Disord; 2008; 8(1):15-20. PubMed ID: 18477966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K
    Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Herbal medicine WangShiBaoChiWan improves gastrointestinal health in mice via modulation of intestinal tight junctions and gut microbiota and inhibition of inflammation.
    Yin S; Sun C; Ji Y; Abdolmaleky H; Zhou JR
    Biomed Pharmacother; 2021 Jun; 138():111426. PubMed ID: 33762124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
    Camilleri M; Lasch K; Zhou W
    Am J Physiol Gastrointest Liver Physiol; 2012 Oct; 303(7):G775-85. PubMed ID: 22837345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Associations of sigmoid colon mucosal mast cells with bowel symptoms and psychological status in patients with irritable bowel syndrome with diarrhea].
    Xu D; Chen W; Zhou WX; Wang CD; Fei GJ; Zhu LM; Xin HW; Zhong DR; Sun G; Fang XC
    Zhonghua Yi Xue Za Zhi; 2016 Aug; 96(30):2398-403. PubMed ID: 27545031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.
    Doyle LA; Sepehr GJ; Hamilton MJ; Akin C; Castells MC; Hornick JL
    Am J Surg Pathol; 2014 Jun; 38(6):832-43. PubMed ID: 24618605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction.
    Zhang C; Huang Y; Li P; Chen X; Liu F; Hou Q
    BMC Complement Med Ther; 2020 Sep; 20(1):279. PubMed ID: 32928188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea.
    Camilleri M; Sellin JH; Barrett KE
    Gastroenterology; 2017 Feb; 152(3):515-532.e2. PubMed ID: 27773805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH
    Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Vivinus-Nébot M; Dainese R; Anty R; Saint-Paul MC; Nano JL; Gonthier N; Marjoux S; Frin-Mathy G; Bernard G; Hébuterne X; Tran A; Theodorou V; Piche T
    Am J Gastroenterol; 2012 Jan; 107(1):75-81. PubMed ID: 21931380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal barrier function is maintained with aging - a comprehensive study in healthy subjects and irritable bowel syndrome patients.
    Wilms E; Troost FJ; Elizalde M; Winkens B; de Vos P; Mujagic Z; Jonkers DMAE; Masclee AAM
    Sci Rep; 2020 Jan; 10(1):475. PubMed ID: 31949225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY; Lu CL; Chen CY; Luo JC
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome.
    Zhou Q; Zhang B; Verne GN
    Pain; 2009 Nov; 146(1-2):41-6. PubMed ID: 19595511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
    Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M
    Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Questions about mesalazine and the irritable bowel syndrome.
    Farup PG
    Aliment Pharmacol Ther; 2011 Oct; 34(8):1036-7; author reply 1037-8. PubMed ID: 21933210
    [No Abstract]   [Full Text] [Related]  

  • 58. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs.
    Kerckhoffs AP; Akkermans LM; de Smet MB; Besselink MG; Hietbrink F; Bartelink IH; Busschers WB; Samsom M; Renooij W
    Dig Dis Sci; 2010 Mar; 55(3):716-23. PubMed ID: 19255843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging therapies in the management of Irritable Bowel Syndrome (IBS).
    Elwing JE; Atassi H; Rogers BD; Sayuk GS
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):55-73. PubMed ID: 35266839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.